[S-(R*,R*)]-6,7-二甲氧基-3-(5,6,7,8-四氢-4-羟基-6-甲基-1,3-二氧杂环戊并[4,5-g]异喹啉-5-基)苯酞 | 521-40-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 邻苯二甲酸异喹啉类
• 中文名称: [S-(R*,R*)]-6,7-二甲氧基-3-(5,6,7,8-四氢-4-羟基-6-甲基-1,3-二氧杂环戊并[4,5-g]异喹啉-5-基)苯酞
• 中文别名: 罌粟殼鹼
• 英文名称: (-)-α-narcotoline
• 英文别名: Narcotoline；(S)-3-((R)-4-hydroxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6,7-dimethoxy-3H-isobenzofuran-1-one；(S)-3-((R)-4-hydroxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6,7-dimethoxy-phthalide；(S)-3-((R)-4-Hydroxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isochinolin-5-yl)-6,7-dimethoxy-phthalid；Narcotolin；(3S)-3-[(5R)-4-hydroxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6,7-dimethoxy-3H-2-benzofuran-1-one
• CAS: 521-40-4
• 化学式: C₂₁H₂₁NO₇
• 分子量: 399.4
• InChiKey: LMGZCSKYOKDBES-AEFFLSMTSA-N

物化性质

• 熔点：
  202°
• 比旋光度：
  D20 -189° (0.1 g in 25 ml chloroform, 20 cm tube); D20 +5.8° (0.065 g in 5 ml 0.1N HCl in 20 cm tube)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  86.7
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  [S-(R*,R*)]-6,7-二甲氧基-3-(5,6,7,8-四氢-4-羟基-6-甲基-1,3-二氧杂环戊并[4,5-g]异喹啉-5-基)苯酞 在 palladium on activated charcoal 氢气 、 potassium carbonate 作用下， 以 乙醇 、 丙酮 为溶剂， 80.0 ℃ 、300.0 kPa 条件下， 反应 33.0h， 生成 北美黄连碱
  参考文献：
  名称：

  Kerekes; Gaal Gy.; Bognar, Acta Chimica Academiae Scientiarum Hungaricae, 1980, vol. 103, # 4, p. 339 - 341

  摘要：

  DOI：

文献信息

• [EN] COMPOSITIONS AND METHODS FOR MAKING NOSCAPINE AND SYNTHESIS INTERMEDIATES THEREOF<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE FABRICATION DE NOSCAPINE ET D'INTERMÉDIAIRES DE SYNTHÈSE DE CELLE-CI
  申请人：EPIMERON INC

  公开号：WO2015021561A1

  公开（公告）日：2015-02-19

  Methods for the manufacture of the therapeutic chemical compound noscapine and noscapine synthesis intermediates comprising contacting a noscapine pathway precursor selected from a first canadine derivative, a first papaveroxine derivative and narcotine hemiacetal with at least one of the enzymes selected from the group CYP82Y1, CYP82X1, AT1, CYP82X2, OMT, CXE1 and NOS.

  制备治疗化合物诺斯卡平和诺斯卡平合成中间体的方法包括将选自第一类肉桂碱衍生物、第一类罂粟碱衍生物和纳科汀半缩醛的诺斯卡平途径前体与来自CYP82Y1、CYP82X1、AT1、CYP82X2、OMT、CXE1和NOS组中至少一种酶中的至少一种接触。
• Method of purifying crude noscapine
  申请人：Marshall Benjamin M.

  公开号：US20100081822A1

  公开（公告）日：2010-04-01

  The invention provides a method for separating noscapine from an opium source without substantially changing the color of the noscapine.

  本发明提供了一种从鸦片源中分离盐酸罂粟碱的方法，而不会显着改变盐酸罂粟碱的颜色。
• Process for production of vinyl chloride polymer
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：EP0172427A2

  公开（公告）日：1986-02-26

  This process is a process for production of a vinyl chloride polymer by suspension polymerization or emulsion polymerization of vinyl chloride monomer or a mixture of vinyl chloride monomer with a vinyl monomer copolymerizable with said vinyl chloride monomer in an aqueous medium, characterized in that the polymerization is carried out in a polymerizer, the inner wall surface and portions of the auxiliary equipment thereof which may come into contact with the monomer during polymerization being previously coated with a scaling preventive comprising at least one selected from dyes, pigments and aromatic or heterocyclic compounds having at least 5 conjugated π bonds, while controlling the chloride ion concentration in the reaction mixture to not higher than 100 ppm. According to said process, scaling onto the inner wall surface of a polymerizer, etc. during polymerization can be prevented effectively and surely.

  该工艺是通过氯乙烯单体或氯乙烯单体与可与所述氯乙烯单体共聚的乙烯基单体混合物在水介质中进行悬浮聚合或乳液聚合来生产氯乙烯聚合物的工艺，其特征在于聚合是在聚合器中进行的、内壁表面及其辅助设备中可能在聚合过程中与单体接触的部分事先涂上一层防垢剂，该防垢剂至少包括一种选自染料、颜料和至少有 5 个共轭 π 键的芳香族或杂环化合物的防垢剂，同时控制反应混合物中的氯离子浓度不高于 100 ppm。根据上述工艺，可有效、可靠地防止聚合过程中聚合器等内壁表面结垢。
• APPLICATION OF PHARMACEUTICAL COMPOSITION IN REGULATION OF FIBROBLAST GROWTH
  申请人：Li, Li

  公开号：EP3711779A1

  公开（公告）日：2020-09-23

  An application of an oral pharmaceutical composition in manufacturing of a medication for regulating fibroblast growth and treating or preventing organ fibrosis. The pharmaceutical composition comprises a homogeneous mixture of an edible oil, beeswax, and β-sitosterol, wherein the beeswax forms microcrystals, and on the basis of the total weight of the composition, the content of the beeswax is 0.5-50% and the content of β-sitosterol is 0.1%-20%.

  一种口服药物组合物在制造调节成纤维细胞生长和治疗或预防器官纤维化的药物中的应用。该药物组合物由食用油、蜂蜡和β-谷甾醇的均匀混合物组成，其中蜂蜡形成微晶，以组合物总重量为基准，蜂蜡的含量为 0.5-50%，β-谷甾醇的含量为 0.1-20%。
• Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids
  申请人：Antheia, Inc.

  公开号：US10544420B2

  公开（公告）日：2020-01-28

  The present disclosure provides systems and methods for increasing production of an alkaloid product through the epimerization of a (S)-1-benzylisoquinoline alkaloid to a (R)-1-benyzlisoquinoline alkaloid via an engineered epimerase in an engineered host cell. A (S)-1-benzylisoquinoline alkaloid is contacted with said engineered epimerase. Contacting said (S)-1-benzylisoquinoline alkaloid with said engineered epimerase converts said (S)-1-benzylisoquinoline alkaloid to said (R)-1-benzylisoquinoline alkaloid.

  本公开提供了通过工程宿主细胞中的工程表聚酶将(S)-1-苄基异喹啉生物碱表聚为(R)-1-苄基异喹啉生物碱来提高生物碱产品产量的系统和方法。将(S)-1-苄基异喹啉生物碱与所述工程表聚酶接触。将所述(S)-1-苄基异喹啉生物碱与所述工程表聚酶接触，将所述(S)-1-苄基异喹啉生物碱转化为所述(R)-1-苄基异喹啉生物碱。